Approaching the golden age of natural product pharmaceuticals from venom libraries: an overview of toxins and toxin-derivatives currently involved in therapeutic or diagnostic applications.
暂无分享,去创建一个
[1] Gail Murphy,et al. Pharmacokinetics and pharmacodynamics of MK‐383, a selective non‐peptide platelet glycoprotein‐IIb/IIIa receptor antagonist, in healthy men , 1994, Clinical pharmacology and therapeutics.
[2] D. Hoppensteadt,et al. Emerging anticoagulant and thrombolytic drugs , 2001, Expert opinion on emerging drugs.
[3] J. Daly,et al. Epibatidine, a potent analgetic and nicotinic agonist. , 1994, Molecular pharmacology.
[4] R. Gould,et al. Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp. , 1994, Journal of medicinal chemistry.
[5] D. Phillips,et al. Clinical pharmacology of eptifibatide. , 1997, The American journal of cardiology.
[6] B. Olivera,et al. Contulakin-G, an O-Glycosylated Invertebrate Neurotensin* , 1999, The Journal of Biological Chemistry.
[7] J. Changeux,et al. Rational understanding of nicotinic receptors drug binding. , 2004, Current topics in medicinal chemistry.
[8] M. Read,et al. Venom coagglutinin for detection of von Willebrand factor activity in animal plasmas. , 1983, The Journal of laboratory and clinical medicine.
[9] M. Bonnet. The toxicology of Heloderma suspectum: the Gila monster , 2000, British Homeopathic Journal.
[10] A. Young,et al. Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). , 1999, Diabetes.
[11] B. Fry. From genome to "venome": molecular origin and evolution of the snake venom proteome inferred from phylogenetic analysis of toxin sequences and related body proteins. , 2005, Genome research.
[12] M. Trikha,et al. Contortrostatin, a snake venom disintegrin, inhibits beta 1 integrin-mediated human metastatic melanoma cell adhesion and blocks experimental metastasis. , 1994, Cancer research.
[13] R. C. Rodríguez de la Vega,et al. Overview of scorpion toxins specific for Na+ channels and related peptides: biodiversity, structure-function relationships and evolution. , 2005, Toxicon : official journal of the International Society on Toxinology.
[14] L. Duong,et al. Isolation, characterization, and cDNA cloning of a vampire bat salivary plasminogen activator. , 1989, The Journal of biological chemistry.
[15] S. Niewiarowski,et al. Trigramin. A low molecular weight peptide inhibiting fibrinogen interaction with platelet receptors expressed on glycoprotein IIb-IIIa complex. , 1987, The Journal of biological chemistry.
[16] C. Toombs. Alfimeprase: Pharmacology of a Novel Fibrinolytic Metalloproteinase for Thrombolysis , 2001, Pathophysiology of Haemostasis and Thrombosis.
[17] M. Esnouf,et al. The Isolation and Properties of the Thrombin‐like Activity from Ancistrodon rhodostoma Venom , 1967, British journal of haematology.
[18] P. Ho,et al. Transcriptome analysis of expressed sequence tags from the venom glands of the fish Thalassophryne nattereri. , 2006, Biochimie.
[19] R. Kini. Venom phospholipase A2 enzymes , 1997 .
[20] Harald Sontheimer,et al. Chlorotoxin Inhibits Glioma Cell Invasion via Matrix Metalloproteinase-2* , 2003, The Journal of Biological Chemistry.
[21] J. Fox,et al. Structural interaction of natural and synthetic inhibitors with the venom metalloproteinase, atrolysin C (form d). , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[22] R. Maroun,et al. Snake venom serine proteinases: sequence homology vs. substrate specificity, a paradox to be solved. , 2005, Toxicon : official journal of the International Society on Toxinology.
[23] M. Watters. Tropical marine neurotoxins: venoms to drugs. , 2005, Seminars in neurology.
[24] G. Tucker. Integrins: Molecular targets in cancer therapy , 2006, Current oncology reports.
[25] Eric J Topol,et al. Platelet GPIIb-IIIa blockers , 1999, The Lancet.
[26] J. Brugge,et al. Structurally distinct disintegrins contortrostatin and multisquamatin differentially regulate platelet tyrosine phosphorylation. , 1994, The Journal of biological chemistry.
[27] J. Raufman,et al. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. , 1992, The Journal of biological chemistry.
[28] L. Lorand,et al. Methods in enzymology. Volume XIX. Proteolytic enzymes. Volume XIX. , 1970 .
[29] M A Ondetti,et al. Angiotensin-converting enzyme inhibitors from the venom of Bothrops jararaca. Isolation, elucidation of structure, and synthesis. , 1971, Biochemistry.
[30] J. Stewart,et al. Bradykinin potentiating peptide PCA-Lys-Trp-Ala-Pro. An inhibitor of the pulmonary inactivation of bradykinin and conversion of angiotensin I to II. , 1971, Biochemical pharmacology.
[31] P. Ho,et al. A survey of gene expression and diversity in the venom glands of the pitviper snake Bothrops insularis through the generation of expressed sequence tags (ESTs). , 2002, Gene.
[32] C. Marcinkiewicz. Functional characteristic of snake venom disintegrins: potential therapeutic implication. , 2005, Current pharmaceutical design.
[33] I. Charo,et al. Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa. , 1993, The Journal of biological chemistry.
[34] A. Harvey,et al. Recent studies on dendrotoxins and potassium ion channels. , 1997, General pharmacology.
[35] K. Garber. Peptide leads new class of chronic pain drugs , 2005, Nature Biotechnology.
[36] C. Roumestand,et al. Scorpion toxins as natural scaffolds for protein engineering. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[37] N. Marsh,et al. The effects of snake venoms on the cardiovascular and haemostatic mechanisms. , 1978, International Journal of Biochemistry.
[38] R. Luther,et al. Pharmacotherapeutic potential of omega-conotoxin MVIIA (SNX-111), an N-type neuronal calcium channel blocker found in the venom of Conus magus. , 1998, Toxicon : official journal of the International Society on Toxinology.
[39] J. Fox,et al. A multifaceted analysis of viperid snake venoms by two‐dimensional gel electrophoresis: An approach to understanding venom proteomics , 2005, Proteomics.
[40] J. Ribeiro,et al. Bitis gabonica (Gaboon viper) snake venom gland: toward a catalog for the full-length transcripts (cDNA) and proteins. , 2004, Gene.
[41] J. Fox,et al. Synthetic and endogenous inhibitors of snake venom metalloproteinases. , 1991, Biomedica biochimica acta.
[42] J. Calvete,et al. Snake venom disintegrins: evolution of structure and function. , 2005, Toxicon : official journal of the International Society on Toxinology.
[43] B. Olivera,et al. Conus venoms: a rich source of novel ion channel-targeted peptides. , 2004, Physiological reviews.
[44] C. Moskaluk,et al. Role of the snake venom toxin jararhagin in proinflammatory pathogenesis: in vitro and in vivo gene expression analysis of the effects of the toxin. , 2005, Archives of biochemistry and biophysics.
[45] J. Vane,et al. The Discovery of Captopril , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[46] A. Colevas,et al. Clinical trials referral resource. Current clinical trials of cilengitide, an alpha(v) antagonist in clinical development as an anticancer agent. , 2004, Oncology.
[47] H. Sontheimer,et al. A role for ion channels in glioma cell invasion. , 2005, Neuron glia biology.
[48] D. Missé,et al. Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes , 2003, Nature Biotechnology.
[49] J. Vane,et al. Some Properties of Angiotensin Converting Enzyme in the Lung in vivo , 1970, Nature.
[50] J. Rosing,et al. Snake Venom Activators of Factor X: An Overview , 2001, Pathophysiology of Haemostasis and Thrombosis.
[51] N. Whittaker,et al. Further classification of skin alkaloids from neotropical poison frogs (Dendrobatidae), with a general survey of toxic/noxious substances in the amphibia. , 1987, Toxicon : official journal of the International Society on Toxinology.
[52] A. Camargo,et al. The Bradykinin-potentiating peptides from venom gland and brain of Bothrops jararaca contain highly site specific inhibitors of the somatic angiotensin-converting enzyme. , 2005, Toxicon : official journal of the International Society on Toxinology.
[53] W. Schleuning. Vampire Bat Plasminogen Activator DSPA-Alpha-1 (Desmoteplase): A Thrombolytic Drug Optimized by Natural Selection , 2001, Pathophysiology of Haemostasis and Thrombosis.
[54] P. Straub,et al. Reptilase®‐R—A New Reagent in Blood Coagulation , 1971, British journal of haematology.
[55] J. Fox,et al. Structural considerations of the snake venom metalloproteinases, key members of the M12 reprolysin family of metalloproteinases. , 2005, Toxicon : official journal of the International Society on Toxinology.
[56] M. Trikha,et al. Purification and characterization of platelet aggregation inhibitors from snake venoms. , 1994, Thrombosis research.
[57] S. Ferreira,et al. Isolation of bradykinin-potentiating peptides from Bothrops jararaca venom. , 1970, Biochemistry.
[58] S. Serrano,et al. Sex-based individual variation of snake venom proteome among eighteen Bothrops jararaca siblings. , 2006, Toxicon : official journal of the International Society on Toxinology.
[59] J. Motsch,et al. Update in the prevention and treatment of deep vein thrombosis and pulmonary embolism , 2006, Current opinion in anaesthesiology.
[60] W. Kisiel,et al. The factor V-activating enzyme (RVV-V) from Russell's viper venom. Identification of isoproteins RVV-V alpha, -V beta, and -V gamma and their complete amino acid sequences. , 1988, The Journal of biological chemistry.
[61] T. Tsuruo,et al. Molecular cloning and functional analysis of apoxin I, a snake venom-derived apoptosis-inducing factor with L-amino acid oxidase activity. , 2000, Biochemistry.
[62] T. Morita. Structures and functions of snake venom CLPs (C-type lectin-like proteins) with anticoagulant-, procoagulant-, and platelet-modulating activities. , 2005, Toxicon : official journal of the International Society on Toxinology.
[63] J. Fox,et al. Comparison of indirect and direct approaches using ion-trap and Fourier transform ion cyclotron resonance mass spectrometry for exploring viperid venom proteomes. , 2006, Toxicon : official journal of the International Society on Toxinology.
[64] G. Strichartz,et al. Purification and characterization of chlorotoxin, a chloride channel ligand from the venom of the scorpion. , 1993, The American journal of physiology.
[65] A. Bosserhoff,et al. Integrin signaling in malignant melanoma , 2005, Cancer and Metastasis Reviews.
[66] J. Charles,et al. A Sino-German λ 6 cm polarization survey of the Galactic plane I . Survey strategy and results for the first survey region , 2006 .
[67] Julian White. Snake venoms and coagulopathy. , 2005, Toxicon : official journal of the International Society on Toxinology.
[68] S. Ferreira. A Bradykinin-Potentiating Factor (BPF) present in the Venom of Bothrops jararaca. , 1965 .
[69] C. M. Bogert,et al. Gila monster: its biology, venom and bite--a review. , 1981, Toxicon : official journal of the International Society on Toxinology.
[70] S. Arneric,et al. ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective antinociceptive agent acting via neuronal nicotinic acetylcholine receptors: II. In vivo characterization. , 1998, The Journal of pharmacology and experimental therapeutics.